Rodin Therapeutics Competitors and Similar CompaniesClear all

Rodin Therapeutics's competitors and similar companies include UCB, Genentech and Cipla.

	Rodin Therapeutics Rodin Therapeutics is discovering and developing first in class therapeutics for neurological disorders, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 2013	Founding Date 1928	Founding Date 1976	Founding Date 1935
Type	Type Subsidiary	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Boston, US HQ	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 1	Employees 9,052	Employees 18,077	Employees 27,764
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods ₹97.2b (FY, 2026)
Gross profit	Gross profit N/A	Gross profit €7.2b (FY, 2025)	Gross profit N/A	Gross profit ₹184.4b (FY, 2026)
Net income	Net income N/A	Net income €1.6b (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)